BioMarin Pharmaceuticals BMRN Business Segments — Cost of Sales
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CostOfRevenue.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's business segments — cost of sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's business segments — cost of sales?
- BioMarin Pharmaceuticals (BMRN) reported business segments — cost of sales of $195M in Q1 2026.
- How has BioMarin Pharmaceuticals's business segments — cost of sales changed year-over-year?
- BioMarin Pharmaceuticals's business segments — cost of sales increased by 28.7% year-over-year, from $151.56M to $195M.
- What is the long-term trend for BioMarin Pharmaceuticals's business segments — cost of sales?
- Over 3 years (2022 to 2025), BioMarin Pharmaceuticals's business segments — cost of sales has grown at a 12.6% compound annual growth rate (CAGR), from $503.02M to $717.44M.
- What does business segments — cost of sales mean?
- The direct costs incurred to manufacture and deliver the products sold by the segment.
- How do you interpret business segments — cost of sales?
- An increase relative to revenue suggests margin compression, while a decrease relative to revenue suggests improved manufacturing efficiency or economies of scale.
- How does business segments — cost of sales compare across companies?
- Comparable to cost of goods sold (COGS) for specific business units in the pharmaceutical industry.